Education
About Us
Working with TipRanks
Follow Us
Vaxcyte, Inc. (PCVX)
NASDAQ:PCVX
PCVX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$27.66 - $121.06
Previous CloseN/A
Volume105.48K
Average Volume (3M)1.22M
Market Cap
$3.89B
Enterprise Value$2.85B
Total Cash (Recent Filing)$1.67B
Total Debt (Recent Filing)$87.21M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Nov 10, 2025EPS Estimate
-1.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.22
Shares Outstanding129,823,350
10 Day Avg. Volume1,338,457
30 Day Avg. Volume1,222,859
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-356.71
Enterprise Value/Ebitda-5.46
Forecast
1Y Price Target
$90.60Price Target Upside202.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Business StrategyPCVX provided positive business updates, including taking steps to increase the odds of delivering compelling VAX-31 Ph2 infant results by adding a new optimized dose.
Financial StabilityThe company reported approximately $3.0B in cash, cash equivalents, and investments, which management now expects to fund operations through mid-2028.
Market PositionIf Pfizer or other companies cannot pursue a 30+ valent vaccine, then VAX-31 will become the new Prevnar because it will have a meaningfully differentiated serotype coverage profile.
Bears Say
Development TimelineThe addition of a new optimized dose to the VAX-31 infant Ph2 should benefit efficacy but will delay the trial completion to 'by the end of 1H27.'
Market ReactionPCVX will trade down in reaction to the extended timelines.
Regulatory EnvironmentAnti-vaccine news flow and regulatory uncertainty out of HHS/FDA, including this week's appointment of Dr. Vinay Prasad as head of CBER, continue to put pressure on shares.
Vaxcyte News
PCVX FAQ
What was Vaxcyte, Inc.’s price range in the past 12 months?
Vaxcyte, Inc. lowest stock price was $27.66 and its highest was $121.06 in the past 12 months.
What is Vaxcyte, Inc.’s market cap?
Vaxcyte, Inc.’s market cap is $3.89B.
When is Vaxcyte, Inc.’s upcoming earnings report date?
Vaxcyte, Inc.’s upcoming earnings report date is Nov 10, 2025 which is in 88 days.
How were Vaxcyte, Inc.’s earnings last quarter?
Vaxcyte, Inc. released its earnings results on Aug 06, 2025. The company reported -$1.22 earnings per share for the quarter, missing the consensus estimate of -$1.16 by -$0.06.
Is Vaxcyte, Inc. overvalued?
According to Wall Street analysts Vaxcyte, Inc.’s price is currently Undervalued.
Does Vaxcyte, Inc. pay dividends?
Vaxcyte, Inc. does not currently pay dividends.
What is Vaxcyte, Inc.’s EPS estimate?
Vaxcyte, Inc.’s EPS estimate is -1.24.
How many shares outstanding does Vaxcyte, Inc. have?
Vaxcyte, Inc. has 129,823,350 shares outstanding.
What happened to Vaxcyte, Inc.’s price movement after its last earnings report?
Vaxcyte, Inc. reported an EPS of -$1.22 in its last earnings report, missing expectations of -$1.16. Following the earnings report the stock price went down -9.061%.
Which hedge fund is a major shareholder of Vaxcyte, Inc.?
Currently, no hedge funds are holding shares in PCVX
Vaxcyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$90.60 (202.00% Upside)
$90.60 (202.00% Upside)
Blogger Sentiment
Bullish
PCVX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.58%
12-Months-Change
Fundamentals
Return on Equity
-21.65%
Trailing 12-Months
Asset Growth
58.36%
Trailing 12-Months
Company Description
Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
PCVX Stock 12 Month Forecast
Average Price Target
$90.60
▲(202.00% Upside)
Technical Analysis
Ownership Overview
0.94% Insiders
45.49% Mutual Funds
0.20% Other Institutional Investors
36.57% Public Companies and
Individual Investors